doi: 10.1021/acschemneuro.5b00135.
Epub 2015 May 26.
Serotonin: A New Hope in Alzheimer's Disease?
Affiliations
- PMID: 26011650
- DOI: 10.1021/acschemneuro.5b00135
Item in Clipboard
Serotonin: A New Hope in Alzheimer's Disease?
ACS Chem Neurosci.
.
Abstract
Alzheimer's disease (AD) is the most common form of dementia affecting 35 million individuals worldwide. Current AD treatments provide only brief symptomatic relief. It is therefore urgent to replace this symptomatic approach with a curative one. Increasing serotonin signaling as well as developing molecules that enhance serotonin concentration in the synaptic cleft have been debated as possible therapeutic strategies to slow the progression of AD. In this Viewpoint, we discuss exciting new insights regarding the modulation of serotonin signaling for AD prevention and therapy.
Keywords: 5-HT4 receptors; 5-HT6 receptors; Serotonin; neuroprotection.
Similar articles
-
Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.Eur J Med Chem. 2016 Oct 4;121:283-293. doi: 10.1016/j.ejmech.2016.05.048. Epub 2016 May 26. Eur J Med Chem. 2016. PMID: 27266998
-
Modulating 5-HT4 and 5-HT6 receptors in Alzheimer's disease treatment.Future Med Chem. 2017 May;9(8):781-795. doi: 10.4155/fmc-2017-0031. Epub 2017 May 15. Future Med Chem. 2017. PMID: 28504917 Review.
-
New insights into serotonin 5-HT4 receptors : a novel therapeutic target for Alzheimer's disease?Curr Alzheimer Res. 2004 May;1(2):79-85. doi: 10.2174/1567205043332252. Curr Alzheimer Res. 2004. PMID: 15975071 Review.
-
Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease.Curr Top Med Chem. 2008;8(12):1035-48. doi: 10.2174/156802608785161420. Curr Top Med Chem. 2008. PMID: 18691131 Review.
-
Chemical update on the potential for serotonin 5-HT6 and 5-HT7 receptor agents in the treatment of Alzheimer's disease.Bioorg Med Chem Lett. 2021 Oct 1;49:128275. doi: 10.1016/j.bmcl.2021.128275. Epub 2021 Jul 23. Bioorg Med Chem Lett. 2021. PMID: 34311086 Review.
Cited by
-
From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer's Disease.Curr Neuropharmacol. 2021;19(6):832-867. doi: 10.2174/1570159X18666200914155951. Curr Neuropharmacol. 2021. PMID: 32928087 Free PMC article. Review.
-
Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's disease.Neuropharmacology. 2020 Sep 1;174:108118. doi: 10.1016/j.neuropharm.2020.108118. Epub 2020 May 4. Neuropharmacology. 2020. PMID: 32380022 Free PMC article. Review.
-
Active Targeted Nanoemulsions for Repurposing of Tegaserod in Alzheimer's Disease Treatment.Pharmaceutics. 2021 Oct 6;13(10):1626. doi: 10.3390/pharmaceutics13101626. Pharmaceutics. 2021. PMID: 34683919 Free PMC article.
-
International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.Pharmacol Rev. 2021 Jan;73(1):310-520. doi: 10.1124/pr.118.015552. Pharmacol Rev. 2021. PMID: 33370241 Free PMC article. Review.
-
5-HIAA induces neprilysin to ameliorate pathophysiology and symptoms in a mouse model for Alzheimer's disease.Acta Neuropathol Commun. 2018 Dec 11;6(1):136. doi: 10.1186/s40478-018-0640-z. Acta Neuropathol Commun. 2018. PMID: 30537985 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
